242 related articles for article (PubMed ID: 23668894)
1. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
Haeusler GM; Slavin MA; Seymour JF; Lingaratnam S; Teh BW; Tam CS; Thursky KA; Worth LJ
Eur J Haematol; 2013 Aug; 91(2):157-63. PubMed ID: 23668894
[TBL] [Abstract][Full Text] [Related]
2. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
3. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine.
Rice ML; Barreto JN; Thompson CA; Mara KC; Tosh PK; Limper AH
Cancer Med; 2021 Aug; 10(15):5120-5130. PubMed ID: 34155819
[TBL] [Abstract][Full Text] [Related]
5. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.
Lingaratnam SM; Slavin MA; Thursky KA; Teh BW; Haeusler GM; Seymour JF; Rischin D; Worth LJ
Leuk Lymphoma; 2015 Jan; 56(1):157-62. PubMed ID: 24717111
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
8. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
[No Abstract] [Full Text] [Related]
9. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide.
Nettleton E; Sattui SE; Wallace Z; Putman M
Arthritis Care Res (Hoboken); 2024 Feb; 76(2):288-294. PubMed ID: 37643919
[TBL] [Abstract][Full Text] [Related]
10. Late-onset Pneumocystis jirovecii pneumonia post-allogeneic stem cell transplantation after time-dependent discontinuation of prophylaxis.
Stavi V; Desai N; Michelis FV; Kim DDH; Kumar R; Lipton JH; Law AD
Eur J Haematol; 2024 Mar; 112(3):433-438. PubMed ID: 37947314
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
12. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis.
Matraiah EH; Olisaka N; Philipos M; Walbaum D; Dospinescu P; Fluck N; Basu N; Kidder D
Clin Rheumatol; 2018 Jul; 37(7):1991-1996. PubMed ID: 29808456
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
14. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
[TBL] [Abstract][Full Text] [Related]
15. Granulomatous Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
Chang H; Shih LY; Wang CW; Chuang WY; Chen CC
Acta Haematol; 2010; 123(1):30-3. PubMed ID: 19940467
[TBL] [Abstract][Full Text] [Related]
16. Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus.
Boone B; Lazaroff SM; Wheless L; Wolfe RM; Barnado A
Semin Arthritis Rheum; 2022 Dec; 57():152106. PubMed ID: 36279805
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
Sidhu VK; Foisy MM; Hughes CA
Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.
Sierra CM; Daiya KC
Pharmacotherapy; 2022 Nov; 42(11):858-867. PubMed ID: 36222368
[TBL] [Abstract][Full Text] [Related]
19. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
20. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
